Can protein kinase C β-selective inhibitor, ruboxistaurin, stop vascular complications in diabetic patients?

Diabetes Care

Volumn 28, Issue 11, 2005, Pages 2803-2805

  He, Zhiheng ^a   King, George L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C BETA;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; EDITORIAL; ENDOTHELIAL DYSFUNCTION; GLYCATION; HUMAN; HYPERGLYCEMIA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RETINOPATHY; VASCULAR DISEASE; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; ENZYMOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; INDOLES; MALEIMIDES; PROTEIN KINASE C; TREATMENT OUTCOME;

EID: 33644802450     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.11.2803     Document Type: Editorial

References (20)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 290:2159-2167, 2003
4. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
5. Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM: RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24: 1342-1349, 2004
6. McClain DA: Hexosamines as mediators of nutrient sensing and regulation in diabetes. J Diabetes Complications 16:72-80, 2002
7. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588, 2002
8. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-2690, 2005
9. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89:11059-11063, 1992
10. Ziyadeh FN, Sharma K: Overview: combating diabetic nephropathy. J Am Soc Nephrol 14:1355-1357, 2003
11. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728-731, 1996
12. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000
13. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018-2026, 1996
14. Abiko T, Abiko A, Clermont AC, Shoelson B, Horio N, Takahashi J, Adamis AP, King GL, Bursell SE: Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 52:829-837, 2003
15. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, Feener EP, Herbert TP, Rhodes CJ, King GL: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101:676-681, 2000
16. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA: Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 90:107-111, 2002
17. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54:2188-2197, 2005
18. Bastyr III E, Price K, Skljarevski V, Lledo A, Vignati L: Ruboxistaurin (RBX) mesylate treatment in patients with diabetic peripheral neuropathy (DPN) improves clinical global impression (CGI) and correlates with change in patient symptoms and signs (Abstract). Diabetes 52 (Suppl. 1):A191, 2003
19. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson-Berka JL, Gilbert RE: Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512-518, 2003
20. Campochiaro PA: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45:922-931, 2004